Concepedia

David Stamler

DS

Statistics

Publications

27

Citations

2.3K

H-Index

22

Active since

1994

Affiliations

Teva Pharmaceuticals (United States)(Current)

Baylor College of Medicine

Teva Pharmaceuticals (Switzerland)

Icahn School of Medicine at Mount Sinai

Teva Pharmaceuticals (Israel)

David Stamler is an author at Teva Pharmaceuticals (United States) specializing in pharmacology, medicine, and neuropharmacology.

Publications per year

1994–2023

27

Publications

27

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease

Samuel Frank, Claudia Testa, David Stamler et al. · JAMA · 2016 · 398 citations · Full text

, , +16

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

Karen E. Anderson, David Stamler, Mat D. Davis et al. · The Lancet Psychiatry · 2017 · 335 citations

, , +9

Randomized controlled trial of deutetrabenazine for tardive dyskinesia

Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser et al. · Neurology · 2017 · 328 citations · Full text

, , +14

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea

Samuel Frank, David Stamler, Elise Kayson et al. · JAMA Neurology · 2017 · 212 citations

, , +14

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six‐month, double‐blind, randomized, dose‐ranging study

Daniel E. Fürst, Kenneth G. Saag, Max Fleischmann et al. · Arthritis & Rheumatism · 2002 · 116 citations

, , +15

1–5 of 27